Can I read Prospective Evaluation of Hydrocortisone and Suramin in Patients with Androgen-independent Prostate Cancer. on EtoBox?

Prospective Evaluation of Hydrocortisone and Suramin in Patients with Androgen-independent Prostate Cancer. by Kelly, W K; Curley, T; Leibretz, C; Dnistrian, A; Schwartz, M; Scher, H I is a Medicine article available to read on EtoBox.

What is Prospective Evaluation of Hydrocortisone and Suramin in Patients with Androgen-independent Prostate Cancer. about?

## PURPOSE To assess efficacy of intermittent infusion of suramin in patients with androgen-independent prostate cancer who have had disease progression on hydrocortisone. ## PATIENTS AND METHODS Chemotherapy-naive patients with progressive androgen-independent prostate cancer were given hydrocortisone 40 mg/d and monitored for treatment effect. At the time of disease progression, suramin was administered on a pharmacokinetically derived, 2-week dosing schedule. ## RESULTS Thirty patients with a median Karnofsky performance status (KPS) of 90% were treated with hydrocortisone. No responses were seen in 12 patients with measurable disease or 29 patients with abnormal bone scans. Thirty patients had an increasing prostate-specific antigen (PSA) level before treatment and six (20%) had a more than 50% decline in PSA from the baseline value for a median of 16 weeks (range, 12 to 52+). Twenty-eight patients had disease progression after a median of 7 weeks (range, 3 to 23), and two patients have continued to receive hydrocortisone for 44 and 52 weeks. Twenty-eight patients received hydrocortisone and suramin, with median suramin concentrations of 97 to 170 micrograms/mL for 4 weeks. No

Who reads Prospective Evaluation of Hydrocortisone and Suramin in Patients with Androgen-independent Prostate Cancer.?

Author

Kelly, W K; Curley, T; Leibretz, C; Dnistrian, A; Schwartz, M; Scher, H I

Publisher

American Society of Clinical Oncology; American Society of Clinical Oncology (ASCO) (ISSN 0732-183X)

Published

1995

Language

EN

Field

Medicine (Health Sciences)